Biogen Pharmachem Industries Limited has announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a profit of ₹25.73 lakh for the second quarter of the fiscal year, with total comprehensive income also standing at ₹25.73 lakh for the same period. For the half-year ended September 30, 2026, the company posted a profit of ₹72.67 lakh.
Biogen Pharmachem Industries Q2 2026 Financial Highlights
Biogen Pharmachem Industries Limited has officially disclosed its unaudited financial results for the quarter and half-year that concluded on September 30, 2026. The Board of Directors approved these results following a meeting held on November 3, 2026.
Quarterly Performance (Q2 FY2026)
For the quarter ended September 30, 2026, Biogen Pharmachem Industries reported a total income from operations of ₹28.33 lakh. The total expenses for the period amounted to ₹2.61 lakh, leading to a profit before tax of ₹25.73 lakh. Consequently, the net profit after tax stood at ₹25.73 lakh, with total comprehensive income for the period also recorded at ₹25.73 lakh. Basic and diluted Earnings Per Share (EPS) were ₹0.00 for the quarter.
Half-Yearly Performance (H1 FY2026)
The company’s financial performance for the six months ended September 30, 2026, showed total income from operations reaching ₹72.67 lakh. Total expenses for the half-year were ₹24.80 lakh. This resulted in a profit before tax of ₹47.87 lakh, and a net profit after tax of ₹47.87 lakh. Total comprehensive income for the half-year was also ₹47.87 lakh. The Earnings Per Share (EPS) for the half-year was ₹0.00 (Basic) and ₹0.00 (Diluted).
Balance Sheet Highlights
As of September 30, 2026, the company’s total assets stood at ₹9,975.57 lakh. Total equity and liabilities were also reported at ₹9,975.57 lakh. Key components of equity include a share capital of ₹10,530.37 lakh, with other equity at a negative ₹573.79 lakh.
Cash Flow Statement Summary
The cash flow statement for the half-year ended September 30, 2026, shows a net cash inflow from operating activities of ₹122.24 lakh. Investing activities generated a net cash inflow of ₹91.34 lakh, while financing activities resulted in a net cash outflow of ₹630.00 lakh. The net increase in cash and cash equivalents for the period was ₹30.89 lakh, bringing the closing balance to ₹1.27 lakh.
Source: BSE
